Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Br J Psychiatry
; 174: 23-30, 1999 Jan.
Article
in En
| MEDLINE
| ID: mdl-10211147
ABSTRACT
BACKGROUND:
Tardive dyskinesia is important in the side-effect profile of antipsychotic medication.AIMS:
The development of tardive dyskinesia was evaluated in patients treated with double-blind, randomly assigned olanzapine or haloperidol for up to 2.6 years.METHODS:
Tardive dyskinesia was assessed by the Abnormal Involuntary Movement Scale (AIMS) and Research Diagnostic Criteria for Tardive Dyskinesia (RD-TD), it was defined as meeting RD-TD criteria at two consecutive assessments. The risk of tardive dyskinesia, the relative risk, incidence rate, and incidence rate ratio were estimated.RESULTS:
The relative risk of tardive dyskinesia for the overall follow up period for haloperidol (n = 522) v. olanzapine (n = 1192) was 2.66 (95% CI = 1.50-4.70). Based on data following the initial six weeks of observation (during which patients underwent medication change and AIMS assessments as frequently as every three days), the one-year risk was 0.52% with olanzapine (n = 513) and 7.45% with haloperidol (n = 114). The relative risk throughout this follow-up period was 11.37 (95% CI = 2.21-58.60).CONCLUSION:
Our results indicated a significantly lower risk of tardive dyskinesia with olanzapine than with haloperidol.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Schizophrenia
/
Antipsychotic Agents
/
Pirenzepine
/
Dyskinesia, Drug-Induced
/
Haloperidol
Type of study:
Clinical_trials
/
Etiology_studies
/
Incidence_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Br J Psychiatry
Year:
1999
Document type:
Article
Affiliation country: